Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CODEPREX vs AMMONIUM CHLORIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Codeine is a prodrug converted to morphine via CYP2D6; morphine acts as a mu-opioid receptor agonist, while homatropine is an anticholinergic that reduces respiratory secretions.
Ammonium chloride is an acidifying agent. It dissociates to ammonium and chloride ions. The ammonium ion is converted to urea in the liver, releasing hydrogen ions, which lower blood and urinary p H. It also increases chloride concentration, promoting excretion of bicarbonate and other bases.
Cough suppression (FDA-approved)
Treatment of metabolic alkalosis,Urinary acidification to enhance excretion of weak bases in poisoning,Expectorant (off-label)
Adults: 1 tablet (containing 5 mg hydrocodone and 325 mg acetaminophen) orally every 4-6 hours as needed for pain; maximum 6 tablets per day.
For metabolic alkalosis: 1-2 g orally 3-4 times daily; or 1 g (as 2 mmol/kg) intravenously over 4-6 hours, repeat as needed based on blood gas analysis.
4-6 hours (prolonged to 10-12 hours in hepatic impairment)
Terminal elimination half-life is approximately 8-12 hours in normal renal function; prolonged in renal impairment (up to 30 hours) due to reliance on renal acid excretion.
Codeine undergoes O-demethylation via CYP2D6 to morphine; also N-demethylation to norcodeine via CYP3A4; homatropine is minimally metabolized.
Ammonium chloride is metabolized in the liver via the urea cycle, where ammonium is converted to urea, consuming bicarbonate and generating hydrogen ions.
Renal: 60% as unchanged drug; Hepatic metabolism: 30% (inactive metabolites); Fecal: 10%
Renal: >99% as ammonium ion (NH4+) and chloride (Cl-), with acid excretion via conversion of NH4+ to urea in liver; minimal biliary/fecal.
92% (primarily to albumin)
<10% bound to plasma proteins (primarily albumin).
1.5-2.0 L/kg (extensive tissue distribution)
Approximately 0.3-0.5 L/kg, distributing mainly in extracellular fluid; minimal intracellular penetration.
Oral: 70-80% (first-pass metabolism reduces from 100% IV)
Oral: 70-80% (subject to first-pass hepatic conversion of NH4+ to urea); intravenous: 100%.
Hydrocodone: GFR 30-80 m L/min: no adjustment; GFR 10-29 m L/min: reduce dose by 50% or extend interval to every 8-12 hours; GFR <10 m L/min: use with caution, consider alternative. Acetaminophen: GFR <10 m L/min: extend dosing interval to every 8 hours.
Contraindicated in severe renal impairment (GFR <30 m L/min). For GFR 30-60 m L/min: reduce dose by 50% and monitor for acidosis. For GFR >60 m L/min: no adjustment necessary.
Child-Pugh Class A: no adjustment; Class B: reduce dose by 50% and extend interval to every 8 hours; Class C: contraindicated due to acetaminophen toxicity risk and impaired hydrocodone metabolism.
No specific Child-Pugh dose adjustments; use with caution in severe hepatic impairment due to risk of encephalopathy.
Not recommended for pediatric use (no safety and efficacy data established).
For metabolic alkalosis: 50-100 mg/kg orally every 6-8 hours, not to exceed 6 g/day. Intravenous: 2-3 mmol/kg over 4-6 hours, repeat based on blood p H.
Start at low end of dosing range (1 tablet every 6 hours) due to increased sensitivity, reduced renal function, and risk of cognitive impairment.
Start at low end of dosing range; monitor renal function and electrolytes closely due to age-related decline in GFR.
Risk of respiratory depression, especially in children; contraindicated for postoperative pain management in children after tonsillectomy/adenoidectomy; contraindicated in children <12 years, and in children <18 years with risk factors for respiratory depression.
None.
Respiratory depression; ultra-rapid metabolizers of CYP2D6 at risk of morphine toxicity; use in breastfeeding may cause infant opioid toxicity; anticholinergic effects of homatropine; risk of abuse and dependence; CNS depression with other depressants.
May cause metabolic acidosis, hyperammonemia in hepatic impairment, and electrolyte disturbances. Use with caution in patients with renal or hepatic disease, pulmonary insufficiency, or cardiac edema.
Hypersensitivity to codeine or homatropine; respiratory depression; acute or severe bronchial asthma; GI obstruction; paralytic ileus; children <12 years; children <18 years with tonsillectomy/adenoidectomy; use with MAOIs or within 14 days; breastfeeding women with CYP2D6 ultrarapid metabolism.
Severe hepatic or renal impairment, primary respiratory acidosis, and patients with uremia or high serum bicarbonate levels.
Grapefruit juice may inhibit CYP2D6 and reduce codeine conversion to morphine, potentially decreasing efficacy. High-fat meals may delay absorption of codeine. Avoid alcohol.
Avoid excessive consumption of alkaline foods (e.g., dairy products, fruits) as they may counteract the acidifying effect. Maintain a consistent diet to avoid fluctuations in acid-base balance.
Based on available data, codeine is pregnancy category C. First trimester: Avoid due to possible association with congenital malformations (e.g., cardiovascular defects) from retrospective studies, though risk is low. Second and third trimesters: Risk of neonatal respiratory depression if used near term; chronic use may lead to neonatal withdrawal syndrome. Avoid if possible.
Ammonium chloride is not associated with major human teratogenicity. However, due to its potential to induce metabolic acidosis, high doses may pose theoretical fetal risks, including fetal acidosis and altered fetal p H homeostasis, particularly in the second and third trimesters. No specific trimester-specific risks are well-documented.
Codeine is excreted into breast milk. M/P ratio is approximately 2.5. Use with caution due to risk of infant CNS depression, especially in mothers who are CYP2D6 ultra-rapid metabolizers. AAP recommends lowest effective dose for shortest duration; monitor infant for drowsiness, difficulty breathing, or poor feeding.
Ammonium chloride is excreted into breast milk in small amounts. The M/P ratio is not well-established. At therapeutic doses, exposure to the nursing infant is likely low and not expected to cause adverse effects. Caution is advised with high doses due to potential for maternal acidosis and subsequent infant effects. Consider monitoring infant for signs of acidosis if maternal therapy is prolonged or high-dose.
No standard dose adjustment required, but avoid use in third trimester due to risk of neonatal respiratory depression. If used, use lowest effective dose for shortest duration. Monitor for signs of maternal respiratory depression; consider reduced dose in patients with decreased respiratory reserve.
Pregnancy increases plasma volume and renal clearance, which may reduce the effectiveness of ammonium chloride as an acidifying agent. Higher doses may be required to achieve therapeutic effect, but this must be balanced against the risk of acidosis. No standard dose-adjustment guidelines exist; dosing should be individualized based on maternal acid-base monitoring. Avoid excessive doses that could cause severe acidosis.
CODEPREX (codeine/guaifenesin) is a combination antitussive/expectorant. Codeine is a prodrug metabolized by CYP2D6 to morphine; ultra-rapid metabolizers risk toxicity. Avoid in children <18 years due to respiratory depression risk. Use with caution in patients with COPD or respiratory insufficiency. Constipation is common; consider prophylactic laxatives.
Ammonium chloride is used as a systemic acidifying agent to treat metabolic alkalosis. Monitor serum electrolytes and acid-base status closely during therapy. Avoid in severe hepatic or renal impairment. Use with caution in patients with respiratory acidosis.
Do not exceed recommended dose; may cause drowsiness, avoid driving or operating machinery until you know how this medication affects you.,Avoid alcohol and other CNS depressants as they increase sedation and respiratory depression risk.,Do not use in children under 18 years of age due to risk of serious breathing problems.,Contact your doctor if cough persists for more than 7 days or is accompanied by fever, rash, or persistent headache.,May cause constipation; increase fluid and fiber intake, and consider a stool softener if needed.,Store at room temperature away from moisture and heat.
Take this medication exactly as prescribed. Do not exceed the recommended dose.,Notify your doctor if you experience nausea, vomiting, confusion, or rapid breathing.,Avoid taking with antacids or alkalinizing agents as they may reduce effectiveness.,Stay hydrated unless otherwise directed by your physician.,Inform your healthcare provider of all medications you are taking, especially diuretics or corticosteroids.
No interactions on record
"Ammonium chloride, an acidifying agent, reduces urinary pH, which increases the renal clearance of lisdexamfetamine and its active metabolite d-amphetamine. This accelerated elimination leads to decreased systemic exposure and potentially diminished therapeutic efficacy of lisdexamfetamine. Clinically, patients may experience reduced symptom control for ADHD or binge eating disorder, requiring dose adjustments or alternative therapies."
"Sufentanil, a potent opioid analgesic, may increase renal excretion of ammonium chloride by promoting diuresis through opioid-induced release of antidiuretic hormone (ADH) and subsequent water reabsorption, leading to dilutional acidosis and enhanced ammonium excretion. This interaction can result in reduced serum ammonium levels and decreased efficacy of ammonium chloride as an acidifying agent, potentially compromising its therapeutic effect in metabolic alkalosis or urinary tract infections. Clinical outcomes may include incomplete correction of metabolic alkalosis or reduced antimicrobial activity of ammonium chloride in the urine."
"Ammonium chloride acidifies the urine, which increases the renal excretion of amphetamine by favoring its ionized form in the tubular lumen, thereby reducing its reabsorption. This leads to a decreased serum concentration of amphetamine and potentially diminished therapeutic efficacy. Clinically, patients may experience reduced mood-elevating or stimulant effects, requiring dose adjustment."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CODEPREX vs AMMONIUM CHLORIDE, answered by our medical review team.
CODEPREX is a Antitussive Combination that works by Codeine is a prodrug converted to morphine via CYP2D6; morphine acts as a mu-opioid receptor agonist, while homatropine is an anticholinergic that reduces respiratory secretions.. AMMONIUM CHLORIDE is a Expectorant/Systemic Acidifier that works by Ammonium chloride is an acidifying agent. It dissociates to ammonium and chloride ions. The ammonium ion is converted to urea in the liver, releasing hydrogen ions, which lower blood and urinary p H. It also increases chloride concentration, promoting excretion of bicarbonate and other bases.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CODEPREX and AMMONIUM CHLORIDE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CODEPREX is: Adults: 1 tablet (containing 5 mg hydrocodone and 325 mg acetaminophen) orally every 4-6 hours as needed for pain; maximum 6 tablets per day.. The standard adult dose of AMMONIUM CHLORIDE is: For metabolic alkalosis: 1-2 g orally 3-4 times daily; or 1 g (as 2 mmol/kg) intravenously over 4-6 hours, repeat as needed based on blood gas analysis.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CODEPREX and AMMONIUM CHLORIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CODEPREX is classified as Category C. Based on available data, codeine is pregnancy category C. First trimester: Avoid due to possible association with congenital malformations (e.g., cardiovascular defects) from retro. AMMONIUM CHLORIDE is classified as Category C. Ammonium chloride is not associated with major human teratogenicity. However, due to its potential to induce metabolic acidosis, high doses may pose theoretical fetal risks, includ. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.